Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
130
resultados
Última actualización
27/06/2025 [07:53:00]
Resultados 75 a 100 de 130
Resumen de: US2025152539A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152542A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152543A1
The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.
Resumen de: WO2024011094A1
The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fausdil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: EP4552634A1
The present disclosure relates to a pharmaceutical composition useful for the prevention or treatment of diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, which includes a sustained-release microsphere containing semaglutide or a pharmaceutically acceptable salt thereof, a bioavailability enhancer and a biodegradable polymer, so that the pharmaceutical composition do not have a high initial burst of drug, contain a high content of drug relative to the particle size and have a high bioavailability, and thus, can minimize pain and inflammatory response of patient that may occur when administered to the human body.
Resumen de: EP4553069A1
Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.
Resumen de: MX2025000057A
The present invention relates to the treatment of a ALS patient with oral fausdil at a dose of 180-240 mg/day, wherein the patient is treated beginning at least 24 months following disease onset. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: KR20250064691A
과제: 부작용이 적거나 없으며, 효과가 우수한 파킨슨병 예방 또는 치료용 약제를 제공하는 것. 해결수단: 본 발명은 세포투과성 PGAM5 (포스포글리세레이트 뮤테이즈 5) 융합단백질을 포함하는 파킨슨병 치료용 약학 조성물에 관한 것으로서, 세포 내로 투과된 PGAM5 융합단백질이 MPP+로 유도한 도파민성 세포사멸과 파킨슨 동물 질환 모델에서 세포 보호효능을 발현하는지를 연구하였다. 그 결과, PGAM5 융합단백질은 파킨슨병에서 효과적인 단백질 치료제로서의 가능성이 있음을 확인하였다.
Resumen de: KR20250065159A
본 발명에서 파킨슨병을 효과적으로 치료할 수 있는 미토콘드리아 치료제를 제공한다. In vitro 실험 결과, 미토콘드리아 치료제(PN-101)는 신경독소에 의해 야기된 세포 사멸을 현저히 감소시켰다. 또한, PN-101은 LPS에 의해 유도된 항염증 사이토카인 발현을 완화시킴을 확인하였다. 뿐만 아니라, In vivo 실험 결과, PN-101은 DA 뉴런에서 신경 보호 효과를 나타내고, 미세아교세포 활성을 억제함으로써, MPTP 유발된 운동 이상을 개선할 수 있음을 확인하였다. 따라서, 미토콘드리아를 개체에 투여시 파킨슨병을 효과적으로 개선하거나 치료할 수 있음을 확인하였다.
Resumen de: KR20250063452A
본 발명은 상염색체우성 알츠하이머병에서 노화 조절을 통한 아밀로이드 병리 제거에 최적 시기 및 방법을 확인하여 완성된 것으로서, 노화세포 표적 약물을 진행된 알츠하이머병 환자에 투여하여 알츠하이머병을 치료하는 방법 등을 제공하여 노화 조절을 통한 새로운 패러다임의 알츠하이머병의 치료적 접근을 가능하게 하며, 상기 방법의 효과적인 치료시기를 제공함으로써 진행된 알츠하이머병 환자를 대상으로 하는 다각적 치료방법의 하나로 이용될 수 있다.
Resumen de: WO2025097160A1
The present disclosure provides methods of enhancing levodopa therapeutic efficacy for the treatment of Parkinson's disease. The present methods can include administration of compounds having a triphenylphosphonium moiety. Advantageously, the present method can mitigate microbial metabolism of levodopa to dopamine in the gut, improve bioavailability of levodopa in brain, and increase dopamine levels in the brain.
Resumen de: WO2025093735A2
The present invention relates to an agent for use in decreasing the level of intracellular phosphorylated tau in neurons, which agent can bind ELAVL4 with a binding affinity of at least - 8.0 kcal/mol. The agent comprises a structural element selected from the group consisting of a steroid backbone, a sugar moiety by glycosidic linkage, an O-linked glucuronide, and a lactone group and is suitably selected from the group of porphyrins, macrolactams, macrolides, vitamin D glucuronides, steroid glucuronides, withanolides, cardenolide glycosides, anthracyclines, ergoloid mesylates, ergotamines and derivates thereof, biphenyls, and piperazines. The administration of said agent leads to a decrease in protein levels of phosphorylated tau in normal neurons treated with the agent as compared to non-treated normal neurons and to a decrease in the Aβ42/Aβ40 ratio in fAD neurons treated with the agent as compared to non-treated fAD neurons. The agent is administered for the treatment of a tauopathy, which may be involved in Alzheimer's disease, frontotemporal dementia, Parkinson's disease or progressive supranuclear palsy and multiple sclerosis.
Resumen de: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Resumen de: US2025145695A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to humanized TDP-43 specific binding molecules, in particular to humanized anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US2025144135A1
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Resumen de: US2025144159A1
A composition comprising a mixture of DHA and/or EPA in the form of glyceride or ethylester derived from at least one microorganism, such as a microalga, and at least one plant-derived phospholipid, in which the content of DHA and/or EPA in triglyceride form is between 10% and 90% by weight relative to the total weight of the composition, and the content of at least one plant-derived phospholipid, such as phosphatidylcholine, is between 10% and 90% by weight relative to the weight of composition. The method for manufacturing same and to the use thereof, in particular in the treatment of pathologies involving a deficiency of DHA and/or EPA, such as age-related macular degeneration or Alzheimer's disease.
Resumen de: US2025146000A1
The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
Resumen de: US2025145722A1
Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Resumen de: WO2025095553A1
A pharmaceutical composition for preventing or treating dementia diseases, containing, as an active ingredient, an isoquinoline derivative compound or a pharmaceutically acceptable salt thereof, of the present invention, does not induce cytotoxicity and can alleviate learning and memory abnormalities in an animal model of Alzheimer's dementia, and thus is expected to be effectively used in the development of therapeutic agents for dementia diseases.
Resumen de: AU2023367200A1
The present disclosure provides methods for achieving optimal levels of bevemipretide (also known as "(R)-2-amino-N-((S)- 1 -(((S)-5-amino- 1 -(3 -benzyl- 1,2,4-oxadiazol-5- yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5- guanidinopentanamide" or "SBT-272"), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, in brain tissue of subjects suspected of having, suffering from, or at risk for a neurodegenerative disease, such as, but not limited to amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), PD with dementia, dementia with Lewy bodies, Multiple System Atrophy, Huntington's disease, HTT proteinopathy, Frontotemporal Lobar Degeneration (FTLD), a tauopathy, and other disease where TDP-43, Tau protein, and α-synuclein are associated with the disease pathology.
Resumen de: EP4549579A1
A composition of the present disclosure contains edaravone and is used for causing a change in expression level of a gene product in a target. The gene product is a gene product of one or more genes selected from KAZALD1, SBK1, SCN2A, UBE2L6, ALPL, NTM, PTTG1, ITGB4, HAUS4, DCTD, MT2A, ASF1B, FCSK, MAST1 and FAIM2. The composition is also suitably used as a pharmaceutical. The composition is also suitably used for treating or preventing a neurodegenerative disease. The neurodegenerative disease is suitably amyotrophic lateral sclerosis (ALS). The present disclosure also provides a method for evaluating responsiveness of edaravone based on an expression level of the gene product or a change in the expression level.
Resumen de: EP4549585A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Resumen de: CN119909151A
The invention belongs to the field of traditional Chinese medicines, discloses a novel application of a gastrodia elata dizziness-relieving preparation, and particularly relates to an application of the gastrodia elata dizziness-relieving preparation in medicines for preventing and treating Parkinson's disease and motor complications thereof. The gastrodia elata dizziness relieving preparation is prepared from 12 raw medicinal materials including gastrodia elata, uncaria, rhizoma alismatis, pinellia ternate, bighead atractylodes rhizome, poria cocos, radix paeoniae alba, caulis bambusae in taeniam, ligusticum wallichii, liquorice, pericarpium citri reticulatae and ginger. Modern pharmacodynamic test research shows that the gastrodia elata dizziness relieving preparation can regulate expression of alpha-synuclein, LC3B and Beclin1 of a Parkinson's disease model rat group, and has a neuroprotective effect on the model rats; the gastrodia elata Jiangning granules have obvious effects of improving behavioristics of Parkinson's disease model mice, and have good prevention and treatment effects on motion fluctuation and dyskinesia of Parkinson's disease and complications of Parkinson's disease.
Resumen de: CN119909093A
The invention belongs to the field of biological medicines, and particularly relates to a composition of chondroitin sulfate oligosaccharide and application of the composition in preparation of a Parkinson's disease treatment medicine. The chondroitin sulfate oligosaccharide is chondroitin sulfate octasaccharide from which a 6-site sulfuric acid group is removed and a 4-site sulfuric acid group is specifically retained; the chondroitin sulfate oligosaccharide oral preparation is a composition containing sodium N-(8-2-hydroxybenzoyl-amino) caprylate (SNAC) and chondroitin sulfate octasaccharide retaining a 4-position sulfuric acid group. The N-(8-2-hydroxybenzoyl-amino) sodium caprylate can effectively promote oral absorption of chondroitin sulfate, and can be used as an oral absorption enhancer; the chondroitin sulfate oligosaccharide has neuroprotective activity and can be used for treating Parkinson's disease.
Nº publicación: CN119912357A 02/05/2025
Solicitante:
GUANGXI UNIV FOR NATIONALITIES
\u5E7F\u897F\u6C11\u65CF\u5927\u5B66
Resumen de: CN119912357A
The invention relates to the technical field of medicinal chemistry and biological medicine, in particular to an alpha-p-aminobenzal-5, 6-dimethoxy-1-indanone derivative as well as a preparation method and application of the alpha-p-aminobenzal-5, 6-dimethoxy-1-indanone derivative. The alpha-p-aminobenzylidene-5, 6-dimethoxy-1-indanone derivative is characterized in that the alpha-p-aminobenzylidene-5, 6-dimethoxy-1-indanone derivative has a structural general formula as shown in a general formula I in the specification. The alpha-p-aminobenzylidene-5, 6-dimethoxy-1-indanone derivative prepared by the invention can be used for preparing a medicine for preventing or treating the Alzheimer's disease, and has an important medicinal value and a wide application prospect in research and development of the medicine for treating the Alzheimer's disease.
BOPI
Sede Electrónica
